PressMarch 11, 2024 Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division
PressMarch 8, 2024 Red Light Holland Commences Experimental Research on Psilocybin Truffles to Develop Process for Commercial Manufacturing of Natural-Source Active Pharmaceutical Ingredient
PressMarch 7, 2024 MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
PressMarch 5, 2024 MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomized Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
PressMarch 5, 2024 Mushrooms Inc. (OTC:MSRM) Launches New Health Supplements, Progresses with German Partnership, and Boosts Engagement Initiatives
PressMarch 4, 2024 BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
PressFebruary 29, 2024 Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
PressFebruary 29, 2024 Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
PressFebruary 29, 2024 atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
PressFebruary 27, 2024 Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110
PressFebruary 27, 2024 Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds
PressFebruary 27, 2024 Red Light Holland to Export Its Largest Batch of Psilocybin to cGMP Lab in Canada, Under a 5th Health Canada Approved Psilocybin Import Permit to Partner CCrest Labs
PressFebruary 26, 2024 FSD Pharma Inc., Subsidiary Enter Agreement for Clinical Trial of Proprietary Blend Beverage
PressFebruary 23, 2024 Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
PressFebruary 21, 2024 Avesta Partners with Veterans Affairs (VA) to Offer Free Ketamine Therapy to Eligible Veterans
